Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 33 results found. Search for [ remdesivir price in US ]

Results 1 to 21 of 33
BusinessToday.In
July 6, 2020
Mylan has been licensed by Gilead for marketing the drug in 127 low- and middle-income countries, including India. The company will manufacture remdesivir at its injectables facilities in India


Reuters
July 4, 2020
A week ago, European Medicines Agency gave its go-ahead for remdesivir to be used in adults and adolescents from 12 years of age who are also suffering from pneumonia and require oxygen support


BusinessToday.In
July 1, 2020
Remdesivir supply: US Department of Health and Human Services said it has secured 500,000 treatment courses of remdesivir for American hospitals through September


Prasanna Mohanty
July 1, 2020
Contrary to popular notion, stock markets have repeatedly demonstrated since the 1929 Great Depression that their performance is not really linked to macroeconomic and business fundamentals


BusinessToday.In
June 30, 2020
In the US, federal health officials have allocated the limited supply to states, but that agreement with Gilead will end after September


Associated Press
New Delhi, June 29, 2020
The 250,000 treatment courses that the company had donated to the US and other countries will run out in about a week, and the prices will apply to the drug after that


BusinessToday.In
New Delhi, June 26, 2020
Coronavirus drug updates: The next batch of Hetero's Remdesivir will be sent to Kolkata, Lucknow, Patna, Indore, Bhopal, Bhubaneshwar, Ranchi, Kochi, Trivandrum, Vijayawada and Goa


Reuters
June 25, 2020
Cipla and Hetero are among a bevy of drugmakers which have licensing agreements with US-based Gilead Sciences Inc, the original manufacturer of remdesivir, to make and sell the drug in 127 low- and middle-income countries


PB Jayakumar
June 24, 2020
Remdesivir, allowed for emergency use in COVID-19 patients from May 1, is currently given as an injection and can be used only in hospitals


Reuters
June 23, 2020
Cipla and privately held Indian drugmaker Hetero Labs on Sunday gained approval to sell generic versions of remdesivir in the country. Hetero expects to price a similar 100 milligram dose of the treatment at 5,000 to 6,000 rupees


BusinessToday.In
June 23, 2020
The government on Tuesday said that it has taken cognizance of the reports in the media about Ayurvedic medicines developed for treatment of coronavirus by Patanjali Ayurved


BusinessToday.In
June 22, 2020
India's Drug Regulator gave permission to Hetero and Cipla to manufacture and market antiviral drug remdesivir for \"restricted emergency use\" on hospitalised COVID-19 patients


BusinessToday.In
June 22, 2020
Stock Market LIVE Updates on June 19: Reliance Industries, Bajaj Finserv, Bajaj Finance, Bajaj Auto, IndusInd Bank and ICICI Bank were among the top gaines on Sensex pack. On the contrary, TCS, ONGC, M&M and Infosys were among the top laggards


BusinessToday.In
June 15, 2020
The agreement will grant the drugmaker right to register, manufacture and sell Gilead's investigational drug, Remdesivir, a potential treatment for Covid-19 in 127 countries including India


BusinessToday.In
June 15, 2020
Stock Market LIVE Updates: IndusInd Bank, followed by Tata Steel, Bajaj Finance, ICICI Bank, Axis Bank, NTPC, SBI, HDFC Bank and SBI were among the top laggards in the Sensex pack. On the other hand, Sun Pharma, Infosys, Nestle India and Asian Paints were among the top gainers


BusinessToday.In
New Delhi, June 8, 2020
Coronavirus treatment: DCGI has asked the five companies concerned to furnish various sets of data including animal toxicity, stability study etc


BusinessToday.In
June 4, 2020
A Gilead spokesperson told the daily that the manufacturers have been given the authority to set their own prices for the drug


PB Jayakumar
May 27, 2020
Approval to explore new COVID-19 therapies, licensing and supply deals to manufacture drugs to treat the virus and fast approvals for plants under regulatory scanner have turned the fortunes of most of these companies


Rupa Burman Roy
May 13, 2020
The market opened higher today as investors were optimistic over the announcement of economic relief package worth Rs 20 lakh crore, up to 10 per cent of the GDP, to help revive economic activity. Meanwhile, FM Sitharaman will announce the details of economic package in phases starting today at 4 PM


BusinessToday.In
May 13, 2020
Jubilant Life Sciences share price opened with a gain of 5% at Rs 429.95 against the previous closing price of Rs 409.50


PAGES 1 OF 2  12